Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Core Viewpoint - Mersana Therapeutics, Inc. is set to provide business updates and report its financial results for Q4 and the full year of 2024 on March 3, 2025, indicating ongoing developments in its clinical-stage biopharmaceutical operations focused on antibody-drug conjugates (ADCs) targeting cancers [1]. Company Overview - Mersana Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel antibody-drug conjugates (ADCs) to address high unmet medical needs in cancer treatment [3]. - The company has developed proprietary ADC platforms, including Dolasynthen and Immunosynthen, which are generating a pipeline of product candidates aimed at treating various cancers [3]. - The pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2) [3].